Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 5Breast Neoplasms 5Endometrial Neoplasms 4Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma, Malignant 1Leiomyosarcoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma, Clear Cell 1Adenocarcinoma of the Oesophagus 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1ATM Gene Mutation 1

Interventions

Gemcitabine 15Doxorubicin 8Docetaxel 8Radiotherapy 7Trabectedin 6Nivolumab 5pazopanib 4liposomal doxorubicin 3Sunitinib 3Dacarbazine 3pembrolizumab 2eribulin 2durvalumab 2avelumab 2Specimen Handling 2Radiation Dose Hypofractionation 2Letrozole 2Ifosfamide 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1temsirolimus 1sotigalimab 1selinexor 1sargramostim 1rucaparib 1ribociclib 1regorafenib 1pegfilgrastim 1olaratumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leiomyosarcoma × rucaparib × Clear all
NCT04624178 2025-11-20

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡